According to FDA Acting Chief Information Officer Amy Abernethy, “The FDA is expediting its work to address the many questions about cannabidiol (CBD),” describing it as “an important national issue with public health impact and an important topic for American hemp farmers and many other stakeholders.”
“We are enthusiastic about research into the therapeutic benefits of CBD products but also need to balance safety,” she said.
During its open call for suggestions related to how cannabis extracts should be regulated, the FDA received more than 4,000 responses from entities ranging from state and local health departments to CBD manufacturers to the American Medical Association.
